ProPhase Labs, Inc. Contract with Customer, Liability, Noncurrent
ProPhase Labs, Inc. (PRPH) had Contract with Customer, Liability, Noncurrent of $348.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2026-08-19
- 2026-06-30: Contract with Customer, Liability, Noncurrent $348.00K.
- 2026-03-31: Contract with Customer, Liability, Noncurrent $788.00K.
- 2025-12-31: Contract with Customer, Liability, Noncurrent $643.00K.
- 2025-09-30: Contract with Customer, Liability, Noncurrent $589.00K.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $348.00K 10-Q · filed 2026-08-19 |
| 2026-03-31 | $788.00K 10-Q/A · filed 2026-07-09 |
| 2025-12-31 | $643.00K 10-Q · filed 2026-08-19 |
| 2025-09-30 | $589.00K 10-Q · filed 2025-11-19 |
| 2025-06-30 | $654.00K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $739.00K 10-Q · filed 2025-05-20 |
| 2024-12-31 | $784.00K 10-K · filed 2026-06-01 |
| 2024-09-30 | $928.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $893.00K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $1.10M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $1.10M 10-K · filed 2025-04-01 |
| 2023-09-30 | $796.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $1.11M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $1.16M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $1.06M 10-K · filed 2024-03-29 |
| 2022-09-30 | $927.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $983.00K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $858.00K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $905.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $106.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $121.00K 10-Q · filed 2021-08-13 |
| 2021-03-31 | $149.00K 10-Q · filed 2021-05-14 |
| 2020-12-31 | $162.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $137.00K 10-Q · filed 2020-11-19 |
| 2020-06-30 | $86.00K 10-Q · filed 2020-08-11 |
| 2020-03-31 | $112.00K 10-Q · filed 2020-05-12 |
| 2019-12-31 | $110.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $129.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $191.00K 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |